Dr Jyoti Bajpai speaks to ecancer about her open-label phase III OLAnzaPiNE trial evaluating low-dose compared to standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in solid tumours.

Dr Bajpai initially talks about the objective and the design of the trial.

The study found that low-dose olanzapine is non-inferior to standard dose in anti-emetic efficacy and results in lower daytime somnolence among patients receiving highly emetogenic chemotherapy and could be a standard of care.